Cationic liposome-mediated incorporation of prostatic acid phosphatase protein into human prostate carcinoma cells

Ming Fong Lin, Julie DaVolio, Renee Garcia

Research output: Contribution to journalArticle

17 Scopus citations


Lipofectin, the commercially available cationic liposome, was used to introduce the purified prostatic acid phosphatase protein into the established human prostate carcinoma cells. The incorporated phosphatase protein which retained its enzymatic activity as demonstrated by the tartrate-sensitive acid phosphatase assay was localized in the cytoplasm by immuriofluorescence staining. Further, cells that were treated with phosphatase/Lipofectin complexes expressed a decreased phosphotyrosine level, presumably due to the endogenous protein tyrosine phosphatase activity of the acid phosphatase protein. A cationic liposome such as lipofectin may thus be employed to mediate transport of other acidic proteins into cells, providing a way to examine their biological functions in vivo.

Original languageEnglish (US)
Pages (from-to)413-419
Number of pages7
JournalBiochemical and Biophysical Research Communications
Issue number2
Publication statusPublished - Apr 30 1993


ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this